Ab­b­Vie touts promis­ing PhI­II da­ta for Orilis­sa as ex­ecs line up their sec­ond pitch and ri­vals lay in wait

Re­searchers for Ab­b­Vie have de­tailed their da­ta from a pair of Phase III uter­ine fi­broid stud­ies for Orilis­sa which they ex­pect will push them to their sec­ond big OK for a drug wide­ly viewed as a block­buster-in-wait­ing.

Al­ready ap­proved for en­dometrio­sis, their drug at 300 mg twice dai­ly eas­i­ly out­paced a place­bo in treat­ing uter­ine fi­broids, with a 68.5% and a 76.2% clin­i­cal re­sponse on the pri­ma­ry end­point for re­duced heavy men­stru­al bleed­ing. The place­bo arms hit 8.7% and 10.1% re­spec­tive­ly, of­fer­ing a sharp and sat­is­fy­ing con­trast for the Ab­b­Vie drug.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.